ClinicalTrials.gg

Program

treprostinil

Also written as “Inhaled Treprostinil”, “treprostinil diethanolamine” and “Oral Treprostinil”.

Its studies are mostly in Pulmonary Arterial Hypertension · Hypertension, Pulmonary · Scleroderma, Systemic · Idiopathic Pulmonary Fibrosis · Chronic Limb-Threatening Ischemia, led by 5 companies.

Furthest: phase 4, since Apr 14, 200371 company-led studies, 9 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
United Therapeutics625 open or runningphase 4since Apr 14, 2003Oct 18, 1999Nov 2027phase 3 · NCT05943535
Liquidia Technologies64 open or runningphase 4since Aug 7, 2026Jan 3, 2018Feb 2027phase 2 · NCT07748000
Mannkind10 open or runningphase 1since Mar 1, 2018Mar 1, 2018none ahead
Pharmosa Biopharm10 open or runningphase 1since Jul 23, 2019Jul 23, 2019none ahead
SciPharm SàRL10 open or runningphase 3since Aug 12, 2011Aug 12, 2011none ahead

Also a collaborator on its studies: ppd-development-lp, nuventra-inc, fgk-clinical-research-gmbh and cvie-therapeutics-co-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Mar 20, 2008.

  1. Mar 4, 2019Phase 2 study in Pulmonary Arterial HypertensionLiquidia Technologies · NCT03884465 · 15 enrolled · France, Germany
  2. May 9, 2019Phase 1 study in Pulmonary Arterial HypertensionUnited Therapeutics · NCT03950739 · 51 enrolled · United States
  3. Jun 5, 2019Phase 3 study in Familial Primary Pulmonary HypertensionLiquidia Technologies · NCT03992755 · 92 enrolled · United States
  4. Jul 23, 2019Pharmosa Biopharm's first study: phase 1 study in Pulmonary Arterial HypertensionNew to Pharmosa BiopharmPharmosa Biopharm · NCT04041648 · 52 enrolled · United States
  5. Jan 12, 2021Phase 3 study in Idiopathic Pulmonary FibrosisUnited Therapeutics · NCT04708782 · 598 enrolled · United States, Canada, Chile
  6. May 20, 2021Phase 3 study in Idiopathic Pulmonary FibrosisUnited Therapeutics · NCT04905693 · 1,850 planned · United States, Argentina, Australia and more
  7. Jan 10, 2022Phase 4 study in Pulmonary Arterial HypertensionUnited Therapeutics · NCT05203510 · 52 enrolled · United States
  8. Feb 15, 2022Phase 3 study in Idiopathic Pulmonary FibrosisUnited Therapeutics · NCT05255991 · 597 enrolled · Argentina, Australia, Belgium and more
  9. Jul 5, 2023Phase 3 study in Lung Diseases, InterstitialUnited Therapeutics · NCT05943535 · 698 planned · United States, Argentina, Australia and more
  10. Dec 11, 2025Phase 3 study in Hypertension, PulmonaryLiquidia Technologies · NCT07285655 · 344 planned · United States, Australia, Austria and more
  11. Jul 31, 2026Phase 2 study in Scleroderma, SystemicLiquidia Technologies · NCT07748000 · 75 planned
  12. Aug 7, 2026Phase 4 study in Pulmonary Arterial HypertensionLiquidia Technologies · NCT07759804 · 20 planned · United States
  13. Oct 19, 2026Phase 2 study in Hypertension, PulmonaryUnited Therapeutics · NCT07923591 · 40 planned · United States
  14. Oct 19, 2026Phase 3 study in Hypertension, PulmonaryUnited Therapeutics · NCT07923526 · 400 planned · United States

Ahead

  1. Feb 2027Primary completion: phase 2 study in Scleroderma, SystemicLiquidia Technologies · NCT07748000
  2. May 2027Primary completion: phase 4 study in Pulmonary Arterial HypertensionLiquidia Technologies · NCT07759804
  3. Nov 2027Primary completion: phase 3 study in Lung Diseases, InterstitialUnited Therapeutics · NCT05943535
  4. May 2028Primary completion: phase 2 study in Hypertension, PulmonaryUnited Therapeutics · NCT07923591

TargetBeta

PTGIR →read by rule
“Prostanoid IP receptor agonist; Prostanoid IP receptor agonist; Prostanoid IP receptor agonist”ChEMBL 37, by rule

Other programs on PTGIR

ProgramCompanyFurthest phaseStudies
selexipagruleJohnson & Johnsonphase 423

Studies

The newest 60 of 71 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07923591Hypertension, Pulmonary · United States2Not yet recruitingUnited TherapeuticsMay 202840
NCT07923526Hypertension, Pulmonary · United States3Not yet recruitingUnited TherapeuticsSep 2034400
NCT07759804Pulmonary Arterial Hypertension · United States4RecruitingLiquidia TechnologiesMay 202720
NCT07748000Scleroderma, Systemic2Not yet recruitingLiquidia TechnologiesFeb 202775
NCT07285655Hypertension, Pulmonary · United States, Australia, Austria and more3RecruitingLiquidia TechnologiesJul 2029344
NCT05943535Lung Diseases, Interstitial · United States, Argentina, Australia and more3RecruitingUnited TherapeuticsNov 2027698
NCT05255991Idiopathic Pulmonary Fibrosis · Argentina, Australia, Belgium and more3CompletedUnited TherapeuticsJun 30, 2025597
NCT05203510Pulmonary Arterial Hypertension · United States4Active, not recruitingUnited TherapeuticsApr 30, 202652
NCT04905693Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more3By invitationUnited TherapeuticsDec 20291,850
NCT04708782Idiopathic Pulmonary Fibrosis · United States, Canada, Chile3CompletedUnited TherapeuticsFeb 2, 2026598
NCT04041648Pulmonary Arterial Hypertension · United States1CompletedPharmosa BiopharmSep 20, 201952
NCT03992755Familial Primary Pulmonary Hypertension · United States3Active, not recruitingLiquidia TechnologiesMay 31, 202592
NCT03950739Pulmonary Arterial Hypertension · United States1CompletedUnited TherapeuticsAug 22, 202351
NCT03884465Pulmonary Arterial Hypertension · France, Germany2TerminatedLiquidia TechnologiesDec 23, 202015
NCT03794583Hypertension, Pulmonary · United States, Israel, Italy3TerminatedUnited TherapeuticsNov 29, 202241
NCT03496623Hypertension, Pulmonary · United States, Argentina, Israel and more3TerminatedUnited TherapeuticsOct 13, 2022188
NCT03497689Pulmonary Arterial Hypertension · United States4CompletedUnited TherapeuticsMay 11, 202236
NCT03464864Pulmonary Arterial Hypertension · United States1CompletedMannkindJun 5, 201836
NCT03399604Familial Primary Pulmonary Hypertension · United States3CompletedLiquidia TechnologiesMay 6, 2019121
NCT03055221Pulmonary Arterial Hypertension4CompletedUnited TherapeuticsFeb 25, 201420
NCT03043651Hypertension, Pulmonary · United States3TerminatedUnited TherapeuticsMar 2, 202048
NCT03055234Pulmonary Hypertension Associated With Sickle Cell Disease3WithdrawnUnited TherapeuticsDec 20210
NCT03037580Hypertension, Pulmonary · United States3TerminatedUnited TherapeuticsDec 3, 201984
NCT03016468Pulmonary Arterial Hypertension2WithdrawnUnited TherapeuticsSep 20180
NCT03012646Hypertension, Pulmonary2WithdrawnUnited TherapeuticsApr 20190
NCT02999906Pulmonary Arterial Hypertension3WithdrawnUnited TherapeuticsDec 20210
NCT02893995Pulmonary Arterial Hypertension · China4WithdrawnUnited TherapeuticsApr 20180
NCT02882126Pulmonary Arterial Hypertension · China4WithdrawnUnited TherapeuticsJun 20210
NCT02847260Pulmonary Arterial Hypertension4CompletedUnited TherapeuticsMar 201439
NCT02633293Hypertension, Pulmonary · United States, Puerto Rico3TerminatedUnited TherapeuticsAug 1, 2021243
NCT02630316Hypertension, Pulmonary · United States, Puerto Rico3CompletedUnited TherapeuticsDec 26, 2019326
NCT02603068Hypertension, Pulmonary · United States2WithdrawnUnited TherapeuticsApr 20180
NCT02276872PAH · United States2CompletedUnited TherapeuticsJul 20, 201732
NCT02318758Healthy · United States1CompletedUnited TherapeuticsOct 201432
NCT02261883Persistent Fetal Circulation Syndrome · United States2TerminatedUnited TherapeuticsSep 27, 202242
NCT01934582Pulmonary Arterial Hypertension · United States3CompletedUnited TherapeuticsNov 201313
NCT01884038Reperfusion Injury · United States3WithdrawnUnited TherapeuticsJun 20100
NCT01746485Healthy · United States1CompletedUnited TherapeuticsJul 201219
NCT01557660Pulmonary Arterial Hypertension3WithdrawnUnited TherapeuticsDec 20180
NCT01557647Pulmonary Arterial Hypertension3WithdrawnUnited TherapeuticsDec 20150
NCT01560637Pulmonary Arterial Hypertension · United States, Argentina, Australia and more3CompletedUnited TherapeuticsAug 12, 2021471
NCT01560624Pulmonary Arterial Hypertension · United States, Argentina, Australia and more3CompletedUnited TherapeuticsJun 24, 2018690
NCT01588405Pulmonary Arterial Hypertension · United States2CompletedUnited TherapeuticsJul 201433
NCT01477333Pulmonary Arterial Hypertension · United States2CompletedUnited TherapeuticsNov 201318
NCT01416636Non-operable Chronic Thromboembolic Pulmonary Hypertension · Austria, Czechia, Germany and more3CompletedSciPharm SàRLNov 2016105
NCT01172496Pulmonary Arterial Hypertension · United States1CompletedUnited TherapeuticsAug 201024
NCT01165476Pulmonary Arterial Hypertension · United States1CompletedUnited TherapeuticsAug 201064
NCT01153386Pulmonary Arterial Hypertension · United States1CompletedUnited TherapeuticsAug 201036
NCT01131845Pulmonary Arterial Hypertension · United States1CompletedUnited TherapeuticsSep 201016
NCT01104870Hypertension, Pulmonary · United States2CompletedUnited TherapeuticsJan 201350
NCT01027949Pulmonary Arterial Hypertension · United States, Australia, Austria and more3CompletedUnited TherapeuticsFeb 12, 2020894
NCT00963027Hypertension, Pulmonary · United States1CompletedUnited TherapeuticsOct 200930
NCT00963001Hypertension, Pulmonary · United States1CompletedUnited TherapeuticsNov 200932
NCT00887978Hypertension, Pulmonary · United States, Belgium, Canada and more3CompletedUnited TherapeuticsJul 2011310
NCT00848939Scleroderma, Systemic · United States1CompletedUnited TherapeuticsJan 201028
NCT00848107Scleroderma, Systemic · United States, Canada, United Kingdom2TerminatedUnited TherapeuticsSep 2011115
NCT00775463Scleroderma, Systemic · United States, Canada, United Kingdom2CompletedUnited TherapeuticsMar 2011148
NCT00760916Hypertension, Pulmonary · United States, Australia, Mexico3WithdrawnUnited TherapeuticsJan 20090
NCT00741819Pulmonary Arterial Hypertension · United States4CompletedUnited TherapeuticsMar 201073
NCT00643604Hypertension, Pulmonary · United States4TerminatedUnited TherapeuticsJan 20107

How it is read

Names in the registry

  • “Inhaled Treprostinil”, 7 entries
  • “treprostinil diethanolamine”, 6 entries
  • “Oral Treprostinil”, 5 entries
  • “treprostinil sodium”, 5 entries
  • “UT-15C SR”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.